NVNO
enVVeno Medical·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 1
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NVNO
Envveno Medical Corporation
An late clinical-stage medical device company focused on the advancement of innovative bioprosthetic (tissue-based) solutions
Healthcare Equipment and Supplies
12/22/1999
05/31/2018
NASDAQ Stock Exchange
37
12-31
Common stock
70 Doppler, Irvine, California 92618
--
EnVVeno Medical Corporation was incorporated in Delaware on December 22, 1999. The company is a late-stage clinical medical device company focused on the advancement of innovative bioprosthesis solutions to improve the standard of care for the treatment of venous diseases. Chronic venous disease (CVD) is the chronic disease with the highest incidence in the world, affecting about 70% of the adult population in the United States. Chronic venous insufficiency (CVI) is a large subset of CVD. It most often occurs in the valves inside the leg veins, resulting in blood reflux (backflow), calf blood bank, increased venous pressure in the legs (venous hypertension), and in severe cases, non-healing venous ulcers. The company is developing surgical and non-surgical replacement venous valves for patients with severe deep vein system CVI in the leg.
Company Financials
EPS
NVNO has released its 2025 Q3 earnings. EPS was reported at -0.23, versus the expected -0.3, beating expectations. The chart below visualizes how NVNO has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
